Image source: Shutterstock

Highlights

  • In FY23, UPR’s operating profit soared by about 27.4% year-on-year to reach €67.71 million, and EBITDA surged by 17.7%
  • The company distributed a final dividend of 1.19 euro cents per share on May 14, 2024
  • The company generated a higher return on equity of 14.4% in FY23 compared to the industry median of 5.8%

Uniphar PLC (LSE: UPR) is a prominent player in the FTSE AIM 100 index providing diversified healthcare services. Catering to the needs of over 200 multinational pharmaceutical and medical technology companies, UPR stands as a crucial provider in the industry. The company has a market capitalization of GBP 580.83 million.

In FY23, the healthcare firm experienced decent growth in its top-line as it expanded by approximately 23.3%, despite persistent macroeconomic uncertainty and inflationary pressures. Its operating profit soared by about 27.4% year-on-year to reach €67.71 million and EBITDA surged by 17.7%. Additionally, the company distributed a final dividend of 1.19 euro cents per share on May 14, 2024, with an ex-dividend date of April 18, 2024.

Uniphar achieved a higher gross margin of 15.3% in FY23 compared to 14.8% in FY22. The company also generated a higher return on equity of 14.4% in FY23 compared to the industry median of 5.8%.

Recent business update

As per the company’s AGM statement dated 09 May 2024, it has reorganized its three new divisions, Uniphar Pharma, Uniphar Medtech, and Uniphar Supply chain and retail.

Company outlook

Backed by McCauley’s acquisition and strategic investment in a new distribution facility, Uniphar sets its sights on an ambitious new target of growing group EBITDA to €200 million over the medium term. Additionally, the company plans to allocate approximately €60 million towards strategic capital expenditure for an IT and ERP investment program. Furthermore, Uniphar PLC's acquisitions of BModesto and Orspec within its product access division will extend its presence into continental Europe and the APAC region, facilitating further growth and expansion, mentions the company.

Top 10 Shareholders

The top 10 shareholders collectively hold about 43.29% of UPR's total shareholdings. Allianz Global Investors GmbH possesses the largest shareholding, accounting for approximately 12.04% of shares. It is followed by Polar Capital LLP with around 7.28% stake, as illustrated in the chart provided.

Stock performance

Over the past month, UPR's share price has dropped approximately 4.20%, while it has seen an increase of around 4.68% over the last six months. Trading between GBX 178.00 and GBX 300.00 over the last 52 weeks, the stock now trades below the midpoint of this 52-week range.

Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference data for all price data, currency, technical indicators, support, and resistance levels is 12 June 2024. The reference data in this report has been partly sourced from EODHD/Others.